Latest News

November 2021

As demands for diversity and equity increase across the globe, a new analysis by the Tufts Center for the Study of Drug Development in Boston, USA, finds nearly 75% of patients who are enrolled in industry-sponsored clinical trials in academic medical centres and community hospitals are white:

csdd.tufts.edu/impact-reports (navigate to press release)

To meet the need for increased output, pharmaceutical companies are embracing an entirely new approach, using the Internet to access instruments and run experiments in a remote lab facility called a “cloud lab” instead of operating physical laboratories of their own:


Researchers from the University of Toronto Faculty of Applied Science & Engineering have developed a polymer coating enabling low surface tension liquids to be transported over distances 15 times longer than currently possible. One of the many potential applications is to miniaturise the standard analytical tests currently preformed in chemical laboratories:


In the UK, the Good Law Project has begun legal proceedings against the Secretary of State for Health and Social Care, Sajid Javid, over the Immensa private laboratory testing scandal in Wolverhampton, in which 43,000 people were given false negative Covid test results:


According to a recent survey from Oracle Health Sciences, 97% of trial professionals say newly adopted approaches (hybrid and decentralised models) will stay in use as we move beyond COVID-19, giving patients more choice in how they participate in trials:


Wellcome Leap, a charity funded by the UK research funder Wellcome, has launched a three-year, US$60-million drive to help researchers develop standardized manufacturing of mRNA in the hope of jumpstarting an entire mRNA industry:


Alva market intelligence group has used the Sustainability Accounting Standards Board (SASB) framework to analyse 20 pharma companies from January 1 to April 30 2021 and produced The top 10 Environmental, Social and Governance (ESG) pharma companies in 2021. Boehringer Ingelheim scored highest:


Britain on 4 November became the first country in the world to approve a potentially game-changing COVID-19 antiviral pill jointly developed by US-based Merck & Co Inc and Ridgeback Biotherapeutics. The pill will be branded as Lagevrio in Britain and is designed to introduce errors into the genetic code of the coronavirus that causes COVID-19:


The inexpensive, generic antidepressant and obsessive-compulsive disorder treatment Fluvoxamine has been shown in clinical trials to significantly reduce the risk of severe illness and death from COVID-19 when prescribed early:


A free one hour online event is on offer from Outsourcing-Pharma on 17th November with a group of experts offering insights, advice, and examples of solutions that put patients at the centre of clinical trials, starting with trial design:



Oracle Partner NCC Group

Customer Area